| Ytd | -5.93% | |
| 1y | -19.87% |
| Open | 5.08 | Prev Close | 5.16 | Low | 5.05 | High | 5.20 | Mkt Cap | 302.96M |
| Vol | 55.39K | Avg Vol | 241.11K | EPS | -1.16 | P/E | -4.45 | Forward P/E | -3.12 |
| Beta | 2.86 | Short Ratio | 7.62 | Inst. Own | 72.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 4.47 | 200-d Avg | 4.86 | 1yr Est | 12.00 |
FHTX News
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being highe
Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contribute
Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cli
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clin
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the anal
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a l
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new cl
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities i
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Rocket Pharmaceuticals (NASDAQ: RCKT - Get
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform a
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant ca
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have been assigned a consensus
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Foghorn Therapeutics (NASDAQ:FHTX)
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cli
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cli
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus ratin
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a cli
Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) has earned an average recommendation of "
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pion
BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy
Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a
Monday saw 196 companies set new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Friday's session saw 466 companies set new 52-week highs.